AbCellera Biologics Inc.
ABCL
$4.05
-$0.13-3.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.88% | -33.36% | 33.06% | -38.39% | 9.06% |
| Total Depreciation and Amortization | 6.89% | 136.49% | -147.26% | 0.68% | 462.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.03% | -42.20% | 384.39% | 55.11% | -220.52% |
| Change in Net Operating Assets | -260.58% | -29.78% | 360.10% | 28.70% | 70.22% |
| Cash from Operations | -180.46% | -44.43% | 72.30% | 3.62% | 28.15% |
| Capital Expenditure | -25.66% | 31.95% | 15.59% | 7.93% | 16.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -199.33% | -63.82% | 131.08% | -69.24% | 33.59% |
| Cash from Investing | -500.89% | -77.77% | 865.47% | -92.90% | 74.18% |
| Total Debt Issued | -10.46% | 4.22% | 90.17% | 9.46% | -6.03% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,888.76% | -0.56% | 3.80% | -0.55% | 1.08% |
| Cash from Financing | -156.53% | 44.13% | 31.70% | 18.63% | -6.36% |
| Foreign Exchange rate Adjustments | 28.98% | 127.31% | -688.56% | 953.49% | 94.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,372.32% | -90.09% | 236.97% | -187.60% | 353.80% |